Prolonged anti-factor Xa level in a patient with moderate renal insufficiency receiving enoxaparin [2]

American Journal of Nephrology

Volumn 22, Issue 4, 2002, Pages 403-404

  Bastani, Bahar ^a   Gonzalez, Esther ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CYCLOPHOSPHAMIDE; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PREDNISONE; WARFARIN;

ADULT; ANTICOAGULATION; CASE REPORT; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIABETIC NEPHROPATHY; DISEASE COURSE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; GLOMERULONEPHRITIS; HUMAN; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY HEMORRHAGE; LABORATORY TEST; LETTER; LUNG EMBOLISM; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK FACTOR; THROMBOEMBOLISM;

ADULT; ANTICOAGULANTS; ENOXAPARIN; FACTOR XA; HUMANS; KIDNEY FAILURE, ACUTE; MALE; TIME FACTORS;

EID: 0036049628     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000065238     Document Type: Letter

References (8)

1. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety
2. Low-molecular-weight heparins
3. A meta-analysis comparing low molecular weight heparins with unfractioned heparin in the treatment of venous thromboembolism
4. Low molecular weight heparins compared with unfractioned heparin for treatment of acute deep venous thrombosis: A meta-analysis of randomized controlled trials
5. Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure
6. Low molecular weight heparin half-life is prolonged in haemodialysed patients
7. Delayed elimination of enoxaparin in patients with chronic renal insufficiency
8. The pharmacology of antithrombotic and antiplatelet agents